vTv Therapeutics study finds 54% of T1D adults on automated insulin delivery report hypoglycemia-related burdens

• vTv Therapeutics flagged new market research on hypoglycemia burdens in adults with type 1 diabetes using automated insulin delivery systems.
• Results were already presented at the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia.
• The analysis found hypoglycemia remains a common, clinically meaningful burden despite wider use of automated insulin delivery technology.
• Management framed the findings as supporting demand for add-on therapies such as its oral investigational cadisegliatin alongside insulin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610100800PRIMZONEFULLFEED9843229) on October 10, 2026, and is solely responsible for the information contained therein.